Applicant: Taro Miyazaki et al. Attorney's Docket No.: 14875-154US1 / C1-A0304P-US

Serial No.: 10/560,098 Filed

: April 28, 2006

Page

: 2 of 12

Amendments to the Specification:

On page 3, line 30, delete the heading "Disclosure of the Invention" and insert therefore -- Summary of the Invention --.

On page 6, line 8, insert the following paragraph:

Brief Description of the Drawings

Fig. 1 shows a graph comparing IFN agonist activities using a quantitative luciferase assay. 2-3: Simultaneous induction; 3-3: tetracycline induction for one day followed by muristerone A induction for two days; 4-4: tetracycline induction for one day followed by muristerone A induction for three days; 5-3: tetracycline induction for two days followed by muristerone A induction for one day; 7-4: muristerone A induction for one day followed by tetracycline induction for three days.

Fig. 2 shows graphs comparing the amounts of antibodies of a desired type by sandwich ELISA. Absorbance at 405 nm with a reference wavelength at 655 nm was measured for each antibody sample at the indicated concentrations. The top graph shows the results for AR1-His+ Antibody + AR2-biotin, and the bottom graph shows the results for AR2-His + Antibody + AR1biotin. Filled circles: samples expressed by simultaneous induction; open squares: samples expressed by induction at different times.

On page 22, delete the paragraph beginning at line 26 thru page 23, line 2.